Colorectal Cancer Dashboard
|
|
- Clementine Hancock
- 6 years ago
- Views:
Transcription
1 Process Risk Assessment Presence or absence of cancer in first-degree blood relatives documented for patients with colorectal cancer Percent of patients with colorectal cancer for whom presence or absence of cancer in first-degree relative was documented Measure 1 Presence or absence of cancer in second-degree blood relatives documented for patients with colorectal cancer Percent of patients with colorectal cancer for whom presence or absence of cancer in seconddegree relative was documented Measure 2 Age at diagnosis documented for each blood relative diagnosed with cancer Percent of patients with colorectal cancer for whom age at diagnosis of blood relative with cancer was documented Measure 3 Patients with invasive colorectal cancer referred for or received genetic testing Patients with increased hereditary risk referred for or received genetic testing Process Appropriateness of Care colorectal cancer who were referred for or received genetic testing colorectal cancer with increased hereditary risk for colon cancer who were referred for or received genetic testing ACoS/CoC 4, ASCO/QOPI 5 ACoS/CoC 6, ASCO/QOPI 7 Colon: Lymph node sampling Percent of surgical patients for which least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer National Average: 12 or more lymph nodes sampled in 41% 8-44% 9 of cases, Best Observed: 85% 10 ; ACoS/CoC CP3R Required Performance Rate: >80%, Ideal Benchmark: >90% 11 ACoS/RQRS 12, AMA-PCPI, ASCO/QOPI 13, NCCN 14, NQF # , PCHQR KRAS testing prior to administration of anti-egfr MoAb therapy Percent of patients with metastatic colorectal cancer tested for KRAS mutation prior to administration of anti-egfr MoAb therapy 30%-40% of metastatic colorectal cancers carry KRAS mutation 16 ; Ideal Benchmark: 100% ASCO/QOPI 17 Anti EGFR MoAb therapy received by patients with KRAS mutation Percent of patients with KRAS mutation who receive anti-egfr MoAb therapy Ideal Benchmark: 0% ASCO/QOPI Measure 18 Rectal: Adjuvant chemotherapy Percent of patients, <80 years of age, with stage II or III rectal cancer for whom post-operative adjuvant chemotherapy was considered or administered of eligible patients ASCO/QOPI 19, NCCN 20 Rectal: Post-operative radiation therapy Percent of patients, <80 years of age, with clinical or pathologic T4N0M0 or stage III rectal cancer receiving surgical resection for whom radiation therapy was considered or administered Ideal Benchmark:100% of eligible patients ACoS/RQRS 21, ASCO 22, NCCN 23 16
2 Process Appropriateness of Care Rate of sphincter-sparing surgery Multimodal therapy for rectal cancer Percent of rectal cancer patients receiving sphincter-sparing surgery Percent of stage II and III rectal cancer patients who received surgery, chemotherapy, and radiation National Average: 60.5% overall 24, Best observed in rectal cancers in lower third % 25, middle - 73%, upper third - 94% 26 ; Ideal benchmark: >70% overall NCDB Average: Stage II 55.8%, Stage III 61.3% 27 ASCO 28, NCCN 29 CEA within 4 months of curative resection for colorectal cancer Percent of patients receiving CEA monitoring within 4 months of curative colorectal cancer resection Measure 30 Colon: Adjuvant chemotherapy Percent of patients with stage III lymph node positive colon cancer, <80 years of age, for whom adjuvant chemotherapy was considered or administered within 4 months (120 days) of surgery National Average: 59% 31 ; of eligible patients 32 ACoS/RQRS 33, AMA-PCPI, ASCO/QOPI 34, NCCN 35, NQF # , PCHQR, PQRS Follow-up: Surveillance for cancer recurrence Percent of patients receiving colonoscopy within 6 months of curative colorectal cancer resection or adjuvant chemotherapy Average Performance: 49% after 14 months 37 ; Ideal Benchmark: >90% AGSE 38, ASCO/QOPI 39, NCCN Enrollment in clinical trials Percent of patients enrolled in clinical trials OR Percent of physicians referring one or more patients to trials per year Only 6% of colorectal cancer patients were aware that clinical trials existed 40. Average percent of physicians referring one or more patients to a clinical trial: medical oncology - 88%, radiation oncology - 66%, surgical oncology - 35% 41 ; CoC Requirement: 4% of all analytic cases across all tumor sites, Ideal Benchmark for patient enrollment: >10% enrollment, Ideal Benchmark for physician participation: 100% of physicians refer 1 or more patients ACoS/CoC 42 Process Patient-Centered Care Pre-test genetic counseling colorectal cancer who were referred for or received pre-test genetic counseling as per ACoS/CoC 2012 Standards 43 ACoS/CoC 44 Post-test genetic counseling colorectal cancer who were referred for or received post-test genetic counseling as per ACoS/CoC 2012 Standards 45 ACoS/CoC 46, ASCO/QOPI 47 17
3 Process Patient-Centered Care Shared decision-making Percent of patients sharing in decision-making regarding surgical options Reported Average: 34% 48 ; of patients who desire an active role in decisionmaking Process Documentation Completeness Colorectal: Pathology report completeness Percent of pathology reports containing all data elements specified by CAP surgical case summary CAP Quality Probe average: 65.7% of colorectal pathology reports complete 49 ; ACoS/CoC Requirement: 90% of pathology reports include required data elements as per CAP protocol 50, Ideal benchmark: 100% ACoS/CoC 51, ASCO/QOPI 52, CAP 53 Colorectal: Staging completeness Percent of patients with complete TNM staging documented in the medical record Reported Averages: 38%- 73% TNM staging completeness 54 ; ACoS/CoC Requirement: 90% of pathology reports include required data elements as per CAP protocol (staging included) 55, Ideal benchmark: 100% ACoS/CoC 56, ASCO/QOPI 57, CAP 58 Outcome Rectal: Surgical margin positivity rate Percent of rectal cancer patients with positive surgical margins Upper middle rectal: 12.6% 59, Low rectal overall: 20% % 61, Low rectal abdominalperineal excision: 30.4% % 63, Low rectal anterior resection 10.7% 64-12% 65 ; Ideal Benchmark: <11% 66 Colon: Surgical margin positivity rate Percent of colon cancer patients with positive surgical margins Best Observed: 11% 67 Anastomotic leaks Percent of surgical patients experiencing anastomotic leak Average: Rectal 3% 68-10% 69, Colon 3% 70 ; Ideal Benchmark: Rectal <5%, Colon <3% Local recurrence rate Percent of patients with locally recurrent cancer within 5-years Average: Colon cancer 18% depending on stage and therapy 71, Rectal cancer: 2-30% depending on stage and therapy (e.g. Local recurrence after mesorectal excision and radiotherapy: 2.4%, Mesorectal excision alone: 8.2%) 72 18
4 Outcome Survival rate: Colon Five-year survival rate by stage at diagnosis All stages 63.6% Localized 90.8% Regional 70.0% Distant 11.7% Unstaged 27.4% By Stage: Stage I - 74% Stage IIA - 67% Stage IIB - 59% Stage IIC - 37% Stage IIIA - 73% Stage IIIB - 46% Stage IIIC - 28% Stave IV - 6% 73 ASCO/QOPI 74 Survival rate: Rectal Five-year survival rate by stage at diagnosis All stages 66.2% Localized 88.0% Regional 68.5% Distant 12.7% Unstaged 45.4% By Stage: Stage I - 74% Stage IIA - 65% Stage IIB - 52% Stage IIC - 32% Stage IIIA - 74% Stage IIIB - 45% Stage IIIC - 33% 75 ASCO/QOPI 76 19
5 Sources 1-3,5,7,13,22,28,39,47,52,57,74,76. American Society of Clinical Oncology, Quality oncology practice initiative: Summary of measures, Spring 2012, available at: pdf, last accessed: August ,6,12,21,33,42,43-46,50,51,55,56. American College of Surgeons, Cancer program standards 2012: Ensuring patient-centered care, 2011, available at: last accessed: August Storli KE, et al., "Overall survival after resection for colon cancer in a national cohort study was adversely affected by TNM stage, lymph node ratio, gender, and old age, International Journal of Colorectal Disease, 2011, 26(10): Baxter NN, et al., "Lymph node evaluation in colorectal cancer patients: A population-based study," Journal of the National Cancer Institute, 2005, 97(3): Stocchi L, et al., Individual surgeon, pathologist, and other factors affecting lymph node harvest in stage II colon carcinoma. Is a minimum of 12 examined lymph nodes sufficient?" Annals of Surgical Oncology, 2011, 18(2): Vather R, et al., "Lymph node evaluation and long-term survival in stage II and stage III colon cancer: A national study, Annals of Surgical Oncology, 2009, 16(3): ,19,29,35. ASCO/NCCN Quality measures: Breast and colorectal cancers, Alexandria (VA): American Society of Clinical Oncology, National Comprehensive Cancer Network, Inc, National Quality Forum, NQF Endorsed Measure #0225, At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer, available at: last accessed: June 20, College of American Pathologists. "KRAS mutation testing for colorectal cancer (CRC)," 2010, published online at: =%2Fportlets%2FcontentViewer%2Fshow&_windowLabel=cntvwrPtlt&cnt vwrptlt%7bactionform.contentreference%7d=committees%2ftechnolog y%2fkras_mutation.html&_state=maximized&_pagelabel=cntvwr 17,18. Allegra CJ, et al., "American society of clinical oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy," Journal of Clinical Oncology, 2009, 27(12): ; Brand TM, Wheeler DL, "KRAS mutant colorectal tumors: Past and present, Small GTPases, 2012, 3(1): ,23. National Comprehensive Cancer Network, National comprehensive cancer network clinical practice guidelines: Rectal cancer, 2010, available at: last accessed August, Paquette IM, et al., "Patient and hospital factors associated with use of sphincter-sparing surgery for rectal cancer," Diseases of the Colon and Rectum, 2010, 53(2): , available at: ital_factors_associated_with_use.2.aspx 25. Elwanis MA, et al.. Surgical treatment for locally advanced lower third rectal cancer after neoadjuvent chemoradiation with capecitabine: prospective phase II trial, World Journal of Surgical Oncology, 2009, 7(52): NP. 26. Di Betta E, et al., "Sphincter saving rectum resection is the standard procedure for low rectal cancer," International Journal of Colorectal Disease, 2003, 18(6): National Cancer Database (NCDB) Benchmark Reports, NCDB Analytic Cases: Rectal Cancer, Diagnosis Year 2009, First course treatment surgery, chemotherapy, radiation, United States, available at: American Society of Clinical Oncology, 2005 Update of ASCO practice guideline recommendations for colorectal cancer surveillance: Guideline summary, 2005, available at: last accessed: August Rayson D., et al., Clinical practice guidelines (CPGs) for adjuvant chemotherapy (act) in colorectal cancer: A population-based analysis of adherence and non-receipt, Journal of Clinical Oncology, 2011, National Quality Forum, NQF Endorsed Measure #0223, Adjuvant chemotherapy is considered or administered within 4 months (120 days) of surgery to patients under the age of 80 with AJCC III (lymph node positive) colon cancer, available at: last accessed: June 20, 2012; Benson AB 3rd, et al., "American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer," Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2004, 22(16): Benson AB 3rd, et al., "American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer," Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2004, 22(16): National Quality Forum, NQF Endorsed Measure #0223 Adjuvant chemotherapy is considered or administered within 4 months (120 days) of surgery to patients under the age of 80 with AJCC III (lymph node positive) colon cancer, available at: last accessed: June 20, Salz T, et al., Variation in use of surveillance colonoscopy among colorectal cancer survivors in the United States, BMC Health Services Research, 2010, Available at: last accessed: August Davila RE et al., "ASGE guideline: Colorectal cancer screening and surveillance, Gastrointestinal Endoscopy, 2006, 63(4):
6 Sources 40. Coalition of Cancer Cooperative Groups, Cancer clinical trials awareness and attitudes in cancer survivors, Spring 2006, available at: Mode=19, last accessed: August Few physicians refer patients to cancer clinical trials, Journal of the National Cancer Institute, 2011, 103 (5): NP, available at: Leon-Carlyle M, et al., "Using patient and physician perspectives to develop a shared decision-making framework for colorectal cancer". Implementation Science, 2009, available at: 26(3): Davila RE, et al., "ASGE guideline: Colorectal cancer screening and surveillance," Gastrointestinal Endoscopy, 2006, 63(4): ,75. Howlader N, et al., SEER cancer statistics review, (Vintage 2009 Populations), Bethesda (MD): National Cancer Institute., 2012, available at: last accessed: June ,53,58. Idowu MO, et al., "Adequacy of surgical pathology reporting of cancer: A college of American pathologists q-probes study of 86 institutions," Archives of Pathology and Laboratory Medicine, 2012, 134(7): Abernethy AP, et al., Poor documentation prevents adequate assessment of quality metrics in colorectal cancer, Journal of Oncology Practice, 2009, 5(4): ,61,62,64. Nagtegaal ID, et al., "Low rectal cancer: a call for a change of approach in abdominoperineal resection, Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2005, 23(36): ,63,65. Shihab OC, et al., "Patients with low rectal cancer treated by abdominoperineal excision have worse tumors and higher involved margin rates compared with patients treated by anterior resection," Diseases of the Colon and Rectum, 2010, 53(1): Salem Health, GI Committee: Clinical dashboards, 2011, available at: last accessed: September Birbeck KF, et al., Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery, Annals of Surgery, 2002, 235(4):449-57; Rullier E, et al., sphincter-saving resection for all rectal carcinomas: The end of the 2-cm distal rule, Annals of Surgery, 2005, 241(3):465-9; Kane et al, Controversies in the surgical management of rectal cancer, Seminars in Radiation Oncology, 2003, 13(4): Smith JD, "Anastomotic leak is not associated with oncologic outcome in patients undergoing low anterior resection for rectal cancer, Annals of Surgery, 2012, Epub ahead of print, available at: last accessed: July Phillips BR, et al. "Anastomotic leak rate after low anterior resection for rectal cancer after chemoradiation therapy," American Surgeon, 2010, 76(8): Hyman N, et al., Anastomotic leaks after intestinal anastomosis: It's later than you think, Annals of Surgery, 2007, 245(2): ; Isbister WH, "Anastomotic leak in colorectal surgery: A single surgeon's experience," The Australian and New Zealand Journal of Surgery, 2001, 71(9): Weiser MR, et al., "Individualized prediction of colon cancer recurrence using a nomogram," Journal of Clinical Oncology, 2008, 21
Cancer Center Dashboard
Cancer Center Dashboard Measure Definition Benchmark Endorsed By Screening Breast Cancer Screening Percentage of eligible women 40-69 who received a mammogram within the past 24 months NCQA reported average:
More informationMeasure Definition Benchmark Endorsed By. Measure Definition Benchmark Endorsed By
Process Risk Assessment Tumor Site: Breast Process Presence or Risk absence Assessment of cancer in first-degree blood relatives documented in patients with invasive breast Presence cancer or absence of
More informationThe New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process
The New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process Wednesday, April 29, 2009 at 11 AM Central M. Asa Carter, CTR Manager, Approvals and Standards
More informationProstate Cancer Dashboard
Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment
More informationColorectal Cancer at the MemorialCare Todd Cancer Institute at Long Beach Memorial
Colorectal Cancer at the MemorialCare Todd Cancer Institute at Long Beach Memorial ANNUAL REPOR T (562) 933-0900 MemorialCare.org/TCI 2810 Long Beach Blvd. Long Beach, CA 90806 #3 Colorectal cancer is
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationDENOMINATOR: Adult patients with metastatic colorectal cancer who have a RAS (KRAS or NRAS) gene mutation
Quality ID #452 (NQF 1860): Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) 4 with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies National Quality Strategy Domain:
More informationIf multiple KRAS mutation tests have been performed, refer to the most recent test results.
Measure #452 (NQF 1860): Patients with Metastatic Colorectal Cancer and KRAS Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies National Quality Strategy
More information!"#$ Oncology Outcomes Report
!"#$ Oncology Outcomes Report The Cleveland Clinic Florida Cancer Institute is dedicated to the comprehensive care of patients with cancer. Oncologists collaborate with a variety of physicians across multiple
More informationCOLON AND RECTAL CANCER
No disclosures COLON AND RECTAL CANCER Mark Sun, MD Clinical Assistant Professor of Surgery University of Minnesota Colon and Rectal Cancer Statistics Overall Incidence 2016 134,490 new cases 8.0% of all
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationCOLON AND RECTAL CANCER
COLON AND RECTAL CANCER Mark Sun, MD Clinical Associate Professor of Surgery University of Minnesota No disclosures Objectives 1) Understand the epidemiology, management, and prognosis of colon and rectal
More informationNATIONAL QUALITY FORUM
Cancer Endorsement Maintenance Table of Submitted Measures Phase I 0210 1 Proportion receiving chemotherapy in the last 14 days of life Percentage of patients who died from cancer receiving chemotherapy
More informationQUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS
QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Quality ID #99 (NQF 0391): Breast Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationCURRENT PRACTICE OF FOLLOW-UP MANAGEMENT AFTER POTENTIALLY CURATIVE RESECTION OF RECTAL CANCER
CURRENT PRACTICE OF FOLLOW-UP MANAGEMENT AFTER POTENTIALLY CURATIVE RESECTION OF RECTAL CANCER 1. a. If you are retired, or do not perform such surgery, please check the box at the right, answer questions
More information11/21/13 CEA: 1.7 WNL
Case Scenario 1 A 70 year-old white male presented to his primary care physician with a recent history of rectal bleeding. He was referred for imaging and a colonoscopy and was found to have adenocarcinoma.
More informationShore Medical Center Site-Specific Study: Colorectal Cancer 2013
Shore Medical Center Site-Specific Study: Colorectal Cancer Shore Medical Center Site-Specific Study: Colorectal Cancer The following report is the result of a collaborative effort of four physician members
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Measure #99 (NQF 0391): Breast Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationCancer Endorsement Maintenance 2011-Maintenance Measures
Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212
More informationANNUAL REPORT. Figure 2 displays the distribution of the number of these diagnoses in 2013 by age (along the X axis) and by gender.
One ANNUAL REPORT Colorectal Cancer Colorectal cancer affects 14, Americans annually, making it the fourth most frequently diagnosed cancer in the US. It is also the second leading cause of cancer death
More informationGuidelines for Laparoscopic Resection of Curable Colon and Rectal Cancer
SAGES Society of American Gastrointestinal and Endoscopic Surgeons http://www.sages.org Guidelines for Laparoscopic Resection of Curable Colon and Rectal Cancer Author : SAGES Webmaster PREAMBLE The following
More informationCancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS)
O COLON MEASURE SPECIFICATIONS Cancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS) Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff
More informationAJCC Cancer Staging 8 th Edition
AJCC Cancer Staging 8 th Edition Colon and Rectal Cancer Staging Update Webinar George J Chang, MD, MS Deputy Chair, Department of Surgical Oncology Chief, Colon and Rectal Surgery Professor of Surgical
More informationColorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY
Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationCollege of American Pathologists. Pathology Performance Measures included in CMS 2012 PQRS
College of American Pathologists Pathology Performance Measures included in CMS 2012 PQRS Breast Cancer Resection Pathology Reporting Measure #99 pt category (primary tumor) and pn category (regional lymph
More informationRectal Cancer. GI Practice Guideline
Rectal Cancer GI Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Dr. Francisco Perera MD, FRCPC (Radiation Oncologist) Dr. Jay Engel MD, FRCPC (Surgical Oncologist) Approval Date: 2006 This guideline
More informationFinancial Disclosure. Learning Objectives. Review and Impact of the NCDB PUF. Moderator: Sandra Wong, MD, MS, FACS, FASCO
Review and Impact of the NCDB PUF Moderator: Sandra Wong, MD, MS, FACS, FASCO Financial Disclosure I do not have personal financial relationships with any commercial interests Learning Objectives At the
More informationLOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent.
Complete as narrative or use the structured format below 55752-0 17.02.28593 Clinical information 22027-7 17.02.30001 Record if different to report header Operating surgeon name and contact details 52101004
More informationreviews Staging, and in the Diagnosis, Managed Care Considerations therapy
reviews therapy Managed Care Considerations in the Diagnosis, Staging, and Treatment of Colorectal Cancer by Johanna Bendell, MD, Director, GI Oncology Research; Associate Director, Drug Development Unit,
More informationCOLORECTAL CARCINOMA
QUICK REFERENCE FOR HEALTHCARE PROVIDERS MANAGEMENT OF COLORECTAL CARCINOMA Ministry of Health Malaysia Malaysian Society of Colorectal Surgeons Malaysian Society of Gastroenterology & Hepatology Malaysian
More informationOriginal Article. Cancer December 1,
Analysis of Stage and Clinical/Prognostic Factors for Colon and Rectal Cancer From SEER Registries: AJCC and Collaborative Stage Data Collection System Vivien W. Chen, PhD 1 ; Mei-Chin Hsieh, MSPH 1 ;
More informationIndex. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,
More informationGastric and Colon Cancer. Dr. Andres Wiernik 2017
Gastric and Colon Cancer Dr. Andres Wiernik 2017 GASTRIC CANCER Gastric Cancer Classification Epidemiology General principles of Management 25% GE Junction Gastric Cancer 75% Gastric Cancer Epidemiology
More information2008 Cancer Committee
2008 Cancer Committee Breast Cancer Study Stages I-III Ina Stafford, CTR JoAnne Schahuber, RT(R) (T) (M) (QM) Table of Cont ent s Table of Contents... 1 Breast Cancer Facts.. 2 CoxHealth Cancer Committee
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominoperineal excision, of rectal cancer, 93 111 current controversies in, 106 109 extent of perineal dissection and removal of pelvic floor,
More informationMEASURE SPECIFICATIONS
QOPI REPTING REGISTRY (QCDR) 2018 QOPI 5 QOPI 11 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Combination chemotherapy
More information2016 CANCER PROGRAM REPORT. Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL
2016 CANCER PROGRAM REPORT Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL 32401 850.769.1511 www.baymedical.org 2016 Cancer Program Report Bay Medical Sacred Heart provides
More informationMEASURE SPECIFICATIONS
QOPI REPTING REGISTRY (QCDR) 2018 QOPI5 Title Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Description Percentage
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationNavigators Lead the Way
RN Navigators Their Role in patients with Cancers of the GI tract Navigators Lead the Way Nurse Navigator Defined Nurse Navigator A clinically trained individual responsible for the identification and
More informationRectal Cancer. Rectal Cancer: The CCF perspective 16/11/2017. Meagan Costedio, MD, FACS, FASCRS. 38,220 new cases estimated in
Rectal Cancer: The CCF perspective Meagan Costedio, MD, FACS, FASCRS Medical Director Colorectal Surgery University Hospitals Ahuja Medical Center Associate Professor - Division of Colorectal Surgery Rectal
More informationStructured Follow-Up after Colorectal Cancer Resection: Overrated. R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007
Structured Follow-Up after Colorectal Cancer Resection: Overrated R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007 Guidelines for Colonoscopy Production: Surveillance US Multi-Society
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationTools, Reports, and Resources
Tools, Reports, and Resources What the National Cancer Database (NCDB) does for CoC-Accredited Programs By using the NCDB, CoC-accredited programs can proactively improve delivery and quality of care for
More informationData and Metrics for Evaluating and Improving Cancer Care Quality in Georgia
Data and Metrics for Evaluating and Improving Cancer Care Quality in Georgia Updates for GATRA on: 1) Augmenting GA Cancer Registry Data to Assess Adherence of Quality-of-Care Metrics 2) Commission on
More informationCOLON CANCER FOLLOW UP GUIDELINES
COLON CANCER FOLLOW UP GUIDELINES CAGPO Dr. Raziya Mia October 1, 2016 1 DISCLOSURES NONE 2 MITIGATING POTENTIAL BIAS Recommendations are consistent with published guidelines American Society of Clinical
More informationDAYS IN PANCREATIC CANCER
HOSPITAL AND MEDICAL CARE DAYS IN PANCREATIC CANCER Annals of Surgical Oncology, March 27, 2012 Casey B. Duncan, Kristin M. Sheffield, Daniel W. Branch, Yimei Han, Yong-Fang g Kuo, James S. Goodwin, Taylor
More informationOne Breast Cancer Annual Report
One 2015 Breast Cancer Annual Report One OVERVIEW The Breast Program at Carolinas HealthCare System s Levine Cancer Institute, offers comprehensive care. Patients with benign and malignant disease of the
More informationBiomarkers to optimize treatment selection in colorectal cancer Edwin Pun HUI, MBChB, MD, FRCP (Lond & Edin)
Recent advances in the management of CRC II 2017/12/17 (Sun.) 10:10-11:00 Biomarkers to optimize treatment selection in colorectal cancer Edwin Pun HUI, MBChB, MD, FRCP (Lond & Edin) Department of Clinical
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. 21 Annual Report Quality Study Adherence to Adjuvant Systemic Therapy Following Primary Surgery in Stage II Breast Cancer Patients: Baylor Scott & White Medical Center Grapevine
More informationOFCCR CLINICAL DIAGNOSIS AND TREATMENT FORM
OFCCR CLINICAL DIAGNOSIS AND TREATMENT FORM Name: _, OFCCR # _ OCGN # _ OCR Group # _ HIN# Sex: MALE FEMALE UNKNOWN Date of Birth: DD MMM YYYY BASELINE DIAGNOSIS & TREATMENT 1. Place of Diagnosis: Name
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. 1 Annual Report Quality Study Adherence to Adjuvant Systemic Therapy Following Primary Surgery in Stage II Breast Cancer Patients: Baylor Scott & White Medical Center McKinney
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationDisclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose
Tumor Budding in Colorectal Carcinoma: What, Why, and How Disclosures I have nothing to disclose Soo-Jin Cho, MD, PhD Assistant Professor UCSF Dept of Pathology Current Issues in Anatomic Pathology 2017
More informationColorectal cancer: pathology
UK NEQAS for Molecular Pathology Colorectal cancer: pathology Nick West Pathology & Tumour Biology May 2013 Colorectal cancer (CRC) 40,695 new cases in 2010 15,708 deaths Management of CRC Surgery Main
More informationDisclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer
Disclosures Colorectal Cancer Update GAFP November 2006 Robert C. Hermann, MD Georgia Center for Oncology Research and Education Northwest Georgia Oncology Centers, PC WellStar Health System Marietta,
More informationRECTAL MEASURE SPECIFICATIONS
Cancer Programs Practice Profile Reports (CP 3 R) RECTAL MEASURE SPECIFICATIONS Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve
More informationCommission on Cancer Updates
Commission on Cancer Updates OBJECTIVES PROVIDE CANCER REGISTRARS WITH INFORMATION ABOUT CURRENT COC 2018 CHANGES DISCUSS CHANGES RELATED TO CANCER REGISTRY DATA COLLECTION DISCUSS CHANGES RELATED TO CANCER
More informationAnaplastic A term used to describe cancer cells that divide rapidly and have little or no resemblance to normal cells.
Oncology Terminology A Adenocarcinoma A cancerous tumor that arises in or resembles glandular tissue. Adjunct agent In cancer therapy, a drug or substance used in addition to the primary therapy. Adjuvant
More informationPharmacy Management Drug Policy
11/13, 10/12, 11/11, 1, 6/10, Page 1 of 5 DESCRIPTION: Cetuximab is a recombinant humanized monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #450 (NQF 1858): Trastuzumab Received By Patients With AJCC Stage I (T1c) III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy National Quality Strategy Domain: Effective Clinical
More informationPublic Reporting of Outcomes 2016
Public Reporting of Outcomes 2016 The Genesis Cancer Care Institute, Genesis Medical Center, Davenport, Iowa is an American College of Surgeon s Commission on Cancer (CoC) accredited program. The CoC is
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. 216 Annual Report Quality Study Adherence to Adjuvant System Therapy Following Primary Surgery in Stage II Breast Cancer Patients: Baylor Scott & White Medical Center Irving
More informationStage: The Language of Cancer
Stage: The Language of Cancer American Joint Committee on Cancer American College of Surgeons Chicago, IL Validating science. Improving patient care. No materials in this presentation may be repurposed
More informationCOLON CANCER CARE GUIDELINES NON-METASTATIC DISEASE
COLON CANCER CARE GUIDELINES NON-METASTATIC DISEASE Guideline Authors: Todd S. Crocenzi, M.D.; Mark Whiteford, M.D.; Matthew Solhjem, M.D.; Carlo Bifulco, M.D.; Melissa Li, M.D.; Christopher Cai, M.D.;
More informationMaking the Most of Your Cancer Registry
www.champsods.com Making the Most of Your Cancer Registry Presenter: Toni Hare, Vice President CHAMPS Oncology Data Services Picture of girl here December 11, 2009 Learning Objectives Upon completion of
More informationEvolution of CoC within ACoS. American College of Surgeons Commission on Cancer Current Activities and Future Initiatives November 5,2005
American College of Surgeons Commission on Cancer Current Activities and Future Initiatives November 5,25 FREDERICK L. GREENE, MD Chair, Commission on Cancer Evolution of CoC within ACoS Two plans proposed
More informationPresent Status and Perspectives of Colorectal Cancer in Asia: Colorectal Cancer Working Group Report in 30th Asia-Pacific Cancer Conference
Present Status and Perspectives of Colorectal Cancer in Asia: Colorectal Cancer Working Group Report in 30th Asia-Pacific Cancer Conference Jpn J Clin Oncol 2010;40(Supplement 1)i38 i43 doi:10.1093/jjco/hyq125
More informationRectal Cancer : Curative treatment without surgery
Rectal Cancer : Curative treatment without surgery Dieter Hahnloser dieter.hahnloser@chuv.ch CHUV University Hospital Lausanne Switzerland Reasons for intervention (surgery) Cure Live longer Feel better
More informationRectal Cancer. Madhulika G. Varma MD Associate Professor and Chief Section of Colorectal Surgery University of California, San Francisco
Rectal Cancer Madhulika G. Varma MD Associate Professor and Chief Section of Colorectal Surgery University of California, San Francisco Modern Treatment for Rectal Cancer Improve Local Control Improved
More informationA916: rectum: adenocarcinoma
General facts of colorectal cancer The colon has cecum, ascending, transverse, descending and sigmoid colon sections. Cancer can start in any of the r sections or in the rectum. The wall of each of these
More informationClinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317
Clinical Policy: (Erbitux) Reference Number: PA.CP.PHAR.317 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients
More informationDifferential lymph node retrieval in rectal cancer: associated factors and effect on survival
Original Article Differential lymph node retrieval in rectal cancer: associated factors and effect on survival Cedrek McFadden 1, Brian McKinley 1, Brian Greenwell 2, Kaylee Knuckolls 1, Patrick Culumovic
More informationFinancial Disclosure. Team. Race-based Socioeconomic and Treatment Disparities in Adolescents and Young Adults with Stage II-III Rectal Cancer
Race-based Socioeconomic and Treatment Disparities in Adolescents and Young Adults with Stage II-III Rectal Cancer Melanie Goldfarb MD, MSc, FACS, FACE John Wayne Cancer Institute at PSJHC, Santa Monica,
More information1. Background. increased sphincter preservation rate. Nonetheless, the 5- year disease-free survival and overall survival rates were
Gastroenterology Research and Practice Volume 2016, Article ID 7870815, 5 pages http://dx.doi.org/10.1155/2016/7870815 Research Article Does Extending the Waiting Time of Low-Rectal Cancer Surgery after
More informationRectal Cancer: Classic Hits
Rectal Cancer: Classic Hits Charles M. Friel, MD Associate Professor of Surgery Section of Colon and Rectal Surgery University of Virginia September 28, 2016 None Disclosures 1 Objectives Review the Classic
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationTerapia neoadyuvante en cáncer de recto Estado del arte Mauricio Lema Medina MD Clínica de Oncología Astorga / Clínica SOMA - Medellín, Colombia
Terapia neoadyuvante en cáncer de recto Estado del arte Mauricio Lema Medina MD Clínica de Oncología Astorga / Clínica SOMA - Medellín, Colombia Temario Generalidades Adyuvancia en colon y recto FU / Capecitabina
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. Annual Report Quality Study Improve process for breast biopsy patients to receive results of pathology reports Background A team from the Baylor Scott & White Medical Center
More informationCurrent Issues and Controversies in the Management of Rectal Cancer
Current Issues and Controversies in the Management of Rectal Cancer Ghazi M. Nsouli MD 11 th Annual Congress of the Lebanese Society of Gastroenterology November 16, 2012 GMN 20121116 1 Staging of rectal
More informationAmerican Society of Clinical Oncology All rights reserved.
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-EGFR Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationQuality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care
Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationLeveraging Your Cancer Registry: A Strategy for Survey Success
CoC-trained consultants on staff Leveraging Your Cancer Registry: A Strategy for Survey Success Toni Hare, RHIT, CTR CoC-trained Consultant Vice President, CHAMPS Oncology November 27, 2012 Georgia s Best
More informationRECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY
COLORECTAL CLINICAL SUBGROUP RECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY Finalised by: Dr Simon Gollins Mr Andrew Renehan Dr Mark Saunders Mr Nigel Scott Dr Shabbir
More informationGeneral Information. Please silence cell phones. Locations Restrooms to the left of the ballroom, or to your right by the elevators
American American College College of of Surgeons 2013 Content 2014 Content cannot be be reproduced or or repurposed without written permission of of the the American College College of Surgeons. of Surgeons.
More informationQuality Measures: How we develop them and the science behind it
Quality Measures: How we develop them and the science behind it Matthew A Facktor MD FACS Geisinger Medical Center Danville PA Sandra L Wong MD MS FACS FASCO Dartmouth Hitchcock Medical Center Lebanon
More informationState-of-the-art of surgery for resectable primary tumors
Early colorectal cancer State-of-the-art of surgery for resectable primary tumors (Special focus on rectal cancer surgery) Stefan Heinrich & Hauke Lang Department of General, Visceral and University Hospital
More information2014 Oncology Measures Group Overview
2014 Oncology Measures Group Overview The Oncology Measures Group is a reporting option that significantly reduces the burden of participation in the Physician Quality Reporting System (PQRS). Source:
More informationPATHOLOGIC FACTORS PROGNOSTIC OF SURVIVAL IN PATIENTS WITH GI TRACT AND PANCREATIC CARCINOMA TREATED WITH NEOADJUVANT THERAPY
PATHOLOGIC FACTORS PROGNOSTIC OF SURVIVAL IN PATIENTS WITH GI TRACT AND PANCREATIC CARCINOMA TREATED WITH NEOADJUVANT THERAPY Jeannelyn S. Estrella, MD Department of Pathology The UT MD Anderson Cancer
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More information